NAGIOS: RODERIC FUNCIONANDO

SOC-V-11 New serum miRNA biomarkers to predict liver steatosis by valproic acid in paediatric epileptic patients

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

SOC-V-11 New serum miRNA biomarkers to predict liver steatosis by valproic acid in paediatric epileptic patients

dc.contributor.author	Jover Atienza, Ramiro
dc.contributor.author	Soluyanova, Polina
dc.contributor.author	Moro Castaño, Emilia
dc.contributor.author	Moreno Torres, Marta
dc.contributor.author	Marco Hernández, Ana Victoria
dc.contributor.author	Tomás Vila, Miguel
dc.contributor.author	Castell Ripoll, José Vicente
dc.date.accessioned	2023-05-19T16:33:49Z
dc.date.available	2023-05-19T16:33:49Z
dc.date.issued	2022
dc.identifier.citation	Jover Atienza, Ramiro Soluyanova, Polina Moro Castaño, Emilia Moreno Torres, Marta Marco Hernández, Ana Victoria Tomás Vila, Miguel Castell Ripoll, José Vicente 2022 SOC-V-11 New serum miRNA biomarkers to predict liver steatosis by valproic acid in paediatric epileptic patients Toxicology Letters 368 2 68
dc.identifier.uri	https://hdl.handle.net/10550/86736
dc.description.abstract	Depakine (Valproate, VPA) has been the first line, most-frequently prescribed, anti-epileptic drug in children for the past 50 years. Idiosyncratic hepatotoxicity (iDILI) by VPA has been demonstrated in several case reports, where microvesicular liver steatosis was the most frequent feature. Moreover, more than half of VPA-treated patients could have silent fatty liver as demonstrated by ultrasounds. Extensive experimental studies support that VPA has a high potential to induce steatosis in hepatocytes. However, there is an apparent lack of significant hepatic problems in the Neuropediatric Units, despite transaminitis is not uncommon. One of the reasons could be that iDILI and liver steatosis diagnosis lack specific biomarkers. Thus, it is likely that a relevant number of children under VPA treatment may have a significant, but sub-clinical, hepatosteatosis.
dc.language.iso	eng
dc.relation.ispartof	Toxicology Letters, 2022, vol. 368, num. 2, p. 68
dc.subject	Farmacèutic i pacient
dc.title	SOC-V-11 New serum miRNA biomarkers to predict liver steatosis by valproic acid in paediatric epileptic patients
dc.type	journal article
dc.date.updated	2023-05-19T16:33:49Z
dc.identifier.doi	10.1016/j.toxlet.2022.07.200
dc.identifier.idgrec	158849
dc.rights.accessRights	open access